Literature DB >> 10572560

The current management of thyroid cancer.

R Udelsman1, H Chen.   

Abstract

Thyroid cancer constitutes 1% of solid organ malignancies. The majority of patients with thyroid carcinoma are cured with adequate surgical management. Table 6 summarizes our standard initial treatment of PTC, follicular cancers, MTC, Hürthle cell carcinomas, thyroid lymphoma, anaplastic carcinoma, and metastases to the thyroid. It is paramount that thyroidectomy be performed by an experienced surgeon to avoid morbidity that would compromise the quality of life in individuals anticipated to enjoy long-term survival.

Entities:  

Mesh:

Year:  1999        PMID: 10572560

Source DB:  PubMed          Journal:  Adv Surg        ISSN: 0065-3411


  23 in total

1.  Surgical audit of inadvertent parathyroidectomy during total thyroidectomy: incidence, risk factors, and outcome.

Authors:  J Rajinikanth; M J Paul; Deepak T Abraham; C K Ben Selvan; Aravindan Nair
Journal:  Medscape J Med       Date:  2009-01-28

Review 2.  Multi-targeted approach in the treatment of thyroid cancer.

Authors:  B Zarebczan; H Chen
Journal:  Minerva Chir       Date:  2010-02       Impact factor: 1.000

3.  Pigment epithelium-derived factor has a role in the progression of papillary thyroid carcinoma by affecting the HIF1α-VEGF signaling pathway.

Authors:  Yichen Lv; Yu Sun; Tiefeng Shi; Chenlei Shi; Huadong Qin; Zhaozhu Li
Journal:  Oncol Lett       Date:  2016-10-25       Impact factor: 2.967

Review 4.  New developments in the diagnosis and treatment of thyroid cancer.

Authors:  David F Schneider; Herbert Chen
Journal:  CA Cancer J Clin       Date:  2013-06-24       Impact factor: 508.702

5.  Xanthohumol inhibits the neuroendocrine transcription factor achaete-scute complex-like 1, suppresses proliferation, and induces phosphorylated ERK1/2 in medullary thyroid cancer.

Authors:  Mackenzie R Cook; Jie Luo; Mary Ndiaye; Herbert Chen; Muthusamy Kunnimalaiyaan
Journal:  Am J Surg       Date:  2010-03       Impact factor: 2.565

6.  Tumor-suppressor role of Notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction.

Authors:  Renata Jaskula-Sztul; Jacob Eide; Sara Tesfazghi; Ajitha Dammalapati; April D Harrison; Xiao-Min Yu; Casi Scheinebeck; Gabrielle Winston-McPherson; Kevin R Kupcho; Matthew B Robers; Amrit K Hundal; Weiping Tang; Herbert Chen
Journal:  Mol Cancer Ther       Date:  2014-12-15       Impact factor: 6.261

7.  Shaw scalpel use for recurrent laryngeal nerve dissection: safety parameter findings from continuous intraoperative neuromonitoring in swine models.

Authors:  Dawon Park; Ji Young You; Hsien Wen Yang; Ralph P Tufano; Hoon Yub Kim
Journal:  Gland Surg       Date:  2020-10

8.  Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride.

Authors:  Joel T Adler; Daniel G Hottinger; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  J Surg Res       Date:  2008-09-04       Impact factor: 2.192

9.  BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China.

Authors:  Xiangqian Zheng; Tingting Xia; Lin Lin; Songyuan Gao; Yigong Lee; Yang Yu; Songfeng Wei; Ming Gao
Journal:  World J Surg Oncol       Date:  2012-06-08       Impact factor: 2.754

10.  Evaluation of the Role of BRAFV600E Somatic Mutation on Papillary Thyroid Cancer Disease Persistence: A Prospective Study.

Authors:  Luca Damiani; Sabrina Lupo; Roberta Rossi; Stefania Bruni; Mirco Bartolomei; Stefano Panareo; Paola Franceschetti; Paolo Carcoforo; Giovanni Lanza; Stefano Pelucchi; Ettore Degli Uberti; Maria Chiara Zatelli
Journal:  Eur Thyroid J       Date:  2018-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.